Abstract: A star polymer of formula O[D1]-([X]-A(D2)-[Z]-[D3])n where O is a core; A is a polymer arm that comprises reactive monomers, hydrophilic monomers and/or charged monomers and is attached to the core; X is a linker molecule between the core and the polymer arm; Z is a linker molecule between the end of the polymer arm and D3; D1 is a drug molecule linked to the core; D2 is a drug molecule linked to reactive monomers distributed along the polymer arm; D3 is a drug molecule linked to the ends of the polymer arms; n is an integer number; [ ] denotes that the group is optional; and D2 is linked to the reactive monomers distributed along the polymer arm at a density of between 1 mol % and 80 mol %.

Abstract: A star polymer of formula O[P1]-([X]-A[P2]-[Z]-[P3])n where O is a core; A is a polymer arm attached to the core; X is a linker molecule between the core and the polymer arm; Z is a linker molecule between the end of the polymer arm and P3; P1, P2 and P3 are each independently one or more pharmaceutically active compounds that act extracellularly or intracellularly, n is an integer number; [ ] denotes that the group is optional; and at least one of P1, P2 or P3 is present.

Abstract: An amphiphilic block copolymer having any one of the formulas S-[B]-H, S-[B]-H(D), D-[B]-H, S-B(D)-H, S-[B]-H-[B]-S, S-[B]-H(D)-[B]-S, D-[B]-H-[B]-S, D-[B]-H-[B]-D, S-B(D)-H-[B]-S or S-B(D)-H-B(D)-S; wherein S is a hydrophilic surface stabilizing group; B is a spacer group; H is a hydrophobic polymer or oligomer; D is a drug molecule; ( ) denotes that the group is bonded directly or indirectly as a side chain or as part of a side chain group to the adjacent group; [ ] denotes that the group is optional; and - denotes that each of the adjacent S, B, H or D are linked directly to one another or indirectly to one another via a linker group.

Abstract: A process for producing a peptide antigen conjugate suitable for administration to a mammal is disclosed. The peptide antigen conjugate comprises a peptide antigen linked to a hydrophobic block. The process comprises reacting a hydrophobic block fragment with a peptide antigen fragment comprising the peptide antigen in a pharmaceutically acceptable organic solvent in a hydrophobic block fragment to peptide antigen fragment molar ratio of 1:1 or greater under conditions to directly or indirectly link the peptide antigen to the hydrophobic block and obtaining a product solution comprising the peptide antigen conjugate, unreacted hydrophobic block fragment and pharmaceutically acceptable organic solvent.

Abstract: Molecularly imprinted particles comprising a label are described herein, in particular such particles prepared by RAFT polymerization, as are compositions and kits comprising such particles, and methods for preparing and using such particles.